Shares of Indoco Remedies were trading 4% below on 20 October after the USFDA (the United States Food and Drug Administration) issued four observations for its Goa Facility.

In its regulatory filing, the company said that the USFDA conducted an inspection at the company’s solid oral formulation facility in Goa between 12 October and 18 October for its two ANDAs (Abbreviated New Drug Applications) filled by the Unit.

At the end of the preapproval inspection, the US regulator issued four observations in Form 483.

The company added that they are committed to addressing these observations within the stipulated time.

The shares of the company hit a 52-week high of Rs 423.10 on 2 January 2023 and a 52-week low of Rs 307 on 26 April.

At 10:50 am, the shares of Natco Pharma were trading 3.70% below at Rs 337.45 on NSE.